LOHMANN, FW and WELZEL, D and BURGER, KJ (1993) CIRCADIAN ANTIHYPERTENSIVE EFFICACY AND TOLERABILITY OF A SLOW-RELEASE ISRADIPINE FORMULATION INTRAINDIVIDUALLY COMPARED WITH NITRENDIPINE. ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 43-1 (5). pp. 522-525. ISSN 0004-4172,
Full text not available from this repository.Abstract
Antihypertensive efficacy and tolerability of a 4-week treatment each with the modified release formulation of the calcium antagonist isradipine (5 mg; Lomir SRO(R), CAS 75695-93-1) were compared with those of nitrendipine (20 mg) (both with morning intake) in 51 patients with mild to moderate hypertension using a double-blind, intraindividual crossover study. Blood pressure was measured over 24 h at the end of a 2-week placebo phase and after both treatment phases by means of a continuous ambulatory recording device. Upon statistical evaluation of all patients with 3 complete 24-h profiles (n = 44) and combined analysis of data from same treatments the following 24-h mean values were obtained: blood pressure (syst./diast.) was lowered from 151/98 mmHg to 141/91 mmHg by isradipine retard (IS) and to 141/92 mmHg by nitrendipine (NI), whereas heart rate remained nearly unchanged (78 vs 79 beats/min on both therapies). The 24-h profiles differed significantly between placebo and both therapies, the profile as a whole was more even on IS. Starting from a day-time mean value (6:00 a.m.-10:00 p.m.) on placebo of 155/102 mmHg blood pressure was reduced by IS to 143/94 mmHg and by NI to 144/95 mmHg; the corresponding night-time mean values were: placebo 138/85 mmHg, IS 132/82 mmHg, NI 134/83 mmHg. If one compares the area under the blood pressure curves during the hours from 6 p.m. to 12 p.m. significant differences (2p = 0.0128) were found for systolic pressure and borderline significance (2p = 0.0668) for diastolic differences in favour of IS. Also tolerability of IS was significantly better: adverse events, typical for dihydropyridines, with relation to study drug were observed in 5 patients on IS (5 entries) and in 11 patients on NI (20 entries). Likewise, the number of nearly normotensive responders on IS (15 out of 44) was greater than that on NI (10 out of 44). Altogether, 5 mg IS has proven more efficacious and tolerable in antihypertensive therapy than 20 mg of NI given once daily.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BLOOD-PRESSURE; HYPERTENSION; THERAPY; ANTIHYPERTENSIVE DRUGS; CALCIUM ANTAGONISTS; CAS-75695-93-1; ISRADIPINE, CLINICAL STUDIES; LOMIR SRO(R); NITRENDIPINE |
| Depositing User: | Dr. Gernot Deinzer |
| Last Modified: | 19 Oct 2022 08:42 |
| URI: | https://pred.uni-regensburg.de/id/eprint/53969 |
Actions (login required)
 |
View Item |
